Wedbush lowered the firm’s price target on Janux Therapeutics (JANX) to $36 from $45 and keeps an Outperform rating on the shares following quarterly results. The firm notes ANX-007 continues to be investigated in taxane-naive mCRPC, with a recent expansion arm combining the PSMA-targeted TRACTr with darolutamide currently underway. Beyond JANX-007, the company is also advancing next generation PSMA-TRACTr JANX014, with a initial clinical development now underway. Finally, Wedbush looks forward to the continued development of preclinical assets, including PSMA-targeted TRACIr JANX013, which is anticipated to enter clinical trials in the second half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics price target lowered to $26 from $30 at Piper Sandler
- Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
- Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
- Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
- Janux Therapeutics reports Q1 EPS (39c), consensus (52c)